|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | | |
| Supplementary Table 1: Studies with outcome data | | | | | | | | | |
| Source | Yr | Total Pts | # Low Risk Pts (%) with (+) & (-) Tn | OUTCOMES FROM EACH OF THE INDIVIDUAL STUDIES | | | | | |
| 30-day PE-related mortality | 30-day A-C mortality | Rec. of PE | Major Bleeding | Primary End-points | Secondary End-points |
| Ahn et al.7 | 2016 | 228 | 36 (16) | NS | 1 | NS | NS | 1 | NS |
| Ozsu et al.8 | 2015 | 206 | 57 (28)  52 Tn-  5 Tn+ | NS  0  NS | 4  1  3 | 0  0  0 | 2  1  1 | 4a  1  3 | 2  1  1 |
| Hakemi et al.9 | 2015 | 298 | 173 (58) | NS | 4 | 0 | 0 | 6a | 0 |
| 89 Tn - | NS | 0 | 0 | 0 | 0 | 0 |
| 84 Tn+ | NS | 4 | 0 | 0 | 6 | 0 |
| Lauque et al.10 | 2014 | 132 | 84 (64) | NS | 1 | 0 | 0 | 1 | 0 |
| 67 Tn- | NS | 0 | 0 | 0 | 0 | 0 |
| 17 Tn+ | NS | 1 | 0 | 0 | 1 | 0 |
| Vuilleumier et al.11 | 2014 | 230 | 81 (35) | NS | NS | 0 | 0 | 6 | 0 |
| Jimenez et al.12 | 2014 | 848 | 313 (37) | NS | NS | 0 | 0 | 5 | 0 |
| Ozsu et al.13 | 2013 | 121 | 45 (37) | 0 | 0 | 0 | 0 | 0 | 0 |
| 31 Tn- | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 Tn+ | 0 | 0 | 0 | 0 | 0 | 0 |
| Sanchez et al.14 | 2013 | 529 | 329 (62)b  278 Tn –  44 Tn+ | NS  NS  NS | 2  NS  NS | 0  0  0 | 0  0  0 | 7  3  4 | 0  0  0 |
| Barra et al.15 | 2012 | 142 | 84 (59) | NS | 5 | 0 | 0 | 5 | 0 |
| Lankeit et al.16 | 2011 | 526 | 198 (38) | NS | 1 | 2 | 4 | 2 | 6 |
| 127 Tn – | 0 | 0 | 1 | 1 | 0 | 2 |
| 71 Tn + | NS | 1 | 1 | 3 | 2 | 4 |
| Sanchez et al.17 | 2011 | 1291 | 407 (32) | 2 | 5 | 0 | 0 | 7 | 0 |
| Spirk et al.18 | 2011 | 369 | 106 (29) | 0 | 0 | 1 | 0 | 1 | 0 |
| Vanni et al.19 | 2011 | 463 | 145 (31) | 1 | 3 | NS | NS | 4a | 3 |
| Jimenez et al.20 | 2011 | 591 | 199 (34) | 1 | 0 | 0 | 0 | 1 | 0 |
| Singanayagam et al.21 | 2010 | 411 | 214 (52) | NS | 1 | 0 | 0 | 1 | 0 |
| Moores et al.22 | 2009 | 567 | 191 (34) | 1 | 1 | 0 | 0 | 2 | 0 |
| 149 Tn – | 1 | 1 | 0 | 0 | 2 | 0 |
| 42 Tn + | 0 | 0 | 0 | 0 | 0 | 0 |

NS = Not Specified, Tn = Troponin, Pts = patients, A-C=all-cause, Rec.=Recurrence

Primary Endpoints = Any primary end-point mentioned in table 1 (30-day or 90-day or 5-day median all-cause or PE-related morality/ CPR/ Mechanical Ventilation/Catecholamine support/Recurrence of PE/major bleeding)

Secondary Endpoints = non-fatal recurrent PE/ non-fatal major bleeding/delayed hemodynamic instability

Note: hemodynamic instability/decompensation = shock = need for catecholamine support

Note: mechanical ventilation = endotracheal intubation

athe duration of the primary end-points of these studies are 90-day, median of 5 days, and “during in-hospital stay” respectively. The remaining of the studies have a 30-day duration.

b7 patients did not have troponins tested